| Metric | Value ($ M) | vs Q2 FY25 |
|---|---|---|
| Revenue | 83.52 | 25.5% |
| Total Income | 83.52 | 25.5% |
| Expenditure | 73.89 | 8.3% |
| PBT | 5.58 | 2526.1% |
| Net Profit | 5.71 | 2384.0% |
| OPM | 11.53% | 13.98pp |
| NPM | 6.84% | 7.21pp |
| EPS | 0.14 | 800.0% |
BillionToOne Reports Q3 2025 Revenue Up 117% to $83.5 Million
04 May 2026 · 4 May, 6:57 am
Summary
BillionToOne reported a significant increase in revenue for the third quarter of 2025, with total revenue reaching $83.5 million, a 117% increase year-over-year. The growth was driven by strong performance in both prenatal and oncology clinical testing revenues. Gross margin also improved significantly, reaching 70% compared to 53% in the same quarter last year. The company expects full year 2025 revenue to be between $293 million and $299 million, representing growth of 92% to 96% compared to full year 2024.
Key Highlights
- 1
Total revenue reached $83.5 million in the third quarter of 2025, representing a 117% increase compared to $38.4 million in the third quarter of 2024.
- 2
Prenatal clinical testing revenue was $74.1 million in the third quarter of 2025, a 102% increase from the same period last year.
- 3
Oncology clinical testing revenue increased 7.6x to $8.7 million in the third quarter of 2025, compared to $1.1 million in the third quarter of 2024.
- 4
Gross margin improved to 70% in the third quarter of 2025, up from 53% in the third quarter of 2024.
- 5
The company accessioned 162,900 tests in the third quarter of 2025, a 51% increase from 107,900 tests in the third quarter of 2024.
- 6
Operating income was $9.6 million in the third quarter of 2025, compared to an operating loss of $12.6 million in the third quarter of 2024.
- 7
BillionToOne expects full year 2025 revenue to be in the range of $293 million to $299 million, representing 92% to 96% growth over last year.
Management Comments
Dr. Oguzhan Atay
This quarter reinforced our view about how a unique, innovative technology combined with disciplined execution can drive a differentiated financial profile in molecular diagnostics. The incredible strength and momentum across our prenatal and oncology businesses reflects a deliberate commitment to scientific rigor paired with resourceful, step-by-step execution. We continue to earn the trust of providers, patients, payors, and health systems, and rapidly grow our test volumes by solving unmet clinical needs. As we begin our path as a public company, we remain guided by the same principles we started with—relentless focus and an unwavering commitment to re-defining molecular diagnostics.”
Informational and educational content only. Not investment advice.